Search

Keegan S Cooke

from Ventura, CA
Age ~56
Get Report
Also known as:
Keegan Jennifer Cooke, Keegan Nancy Cooke, Keegan C Ooke, Keegan Cook, Cooke Spencer Keegan
Phone and address:
85 Parkhill Cir, Ventura, CA 93003
(805) 654-9983
Related to:
Juliet Marie Engelhart, 49
Connected to:
Abigail L Cooke, 48Alexis P Cooke, 50Andreal Cooke, 51Angie Cooke, 53Annika M Cooke, 37Arnold B Cooke, 71Ashanti Cooke, 44Astrid K Cooke, 71Becky Y Cooke, 59Brenden R Cooke, 31

Keegan Cooke Phones & Addresses

  • 85 Parkhill Cir, Ventura, CA 93003 (805) 654-9983
  • 574 San Clemente St, Ventura, CA 93001 (805) 653-6165
  • 3086 Bayshore Ave, Ventura, CA 93001 (805) 642-3111
  • Camarillo, CA
  • Palo Alto, CA
  • Goleta, CA
  • Oxnard, CA
  • San Ramon, CA
  • 85 Parkhill Cir, Ventura, CA 93003

Work

Company: Amgen Aug 2003 Position: Research scientist

Education

Degree: Bachelors, Bachelor of Arts School / High School: Uc Santa Barbara 1987 to 1991 Specialities: Microbiology

Skills

Drug Discovery • Assay Development • Monoclonal Antibodies • Biotechnology • Antibodies

Languages

English

Industries

Biotechnology

Resumes

Resumes

Keegan Cooke Photo 1

Research Scientist

View page
Location:
85 Parkhill Cir, Ventura, CA 93003
Industry:
Biotechnology
Work:
Amgen
Research Scientist
Remedyne Apr 2001 - Feb 2003
Scientist
Amgen 1997 - 2001
Associate Scientist
Cell Genesys 1992 - 1997
Associate Scientist
Amgen 1990 - 1992
Research Associate
Education:
Uc Santa Barbara 1987 - 1991
Bachelors, Bachelor of Arts, Microbiology Uc Santa Barbara 1987 - 1991
Masters, Master of Arts, Microbiology
Skills:
Drug Discovery
Assay Development
Monoclonal Antibodies
Biotechnology
Antibodies
Languages:
English

Publications

Us Patents

Method For Production Of High Titer Virus And High Efficiency Retroviral Mediated Transduction Of Mammalian Cells

View page
US Patent:
6506604, Jan 14, 2003
Filed:
Sep 4, 2001
Appl. No.:
09/944411
Inventors:
Mitchell H. Finer - San Carlos CA
Thomas J. Dull - San Francisco CA
Krisztina M. Zsebo - Woodside CA
Keegan Cooke - Palo Alto CA
Deborah A. Farson - Oakland CA
Assignee:
Cell Genesys, Inc. - Foster City CA
International Classification:
C12N 15867
US Classification:
435456, 4353201, 4352351, 435325, 435455, 435457, 536 231, 536 241, 536 232, 536 2372
Abstract:
The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and, human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.

Hepcidin, Hepcidin Antagonists And Methods Of Use

View page
US Patent:
8629250, Jan 14, 2014
Filed:
Jan 30, 2008
Appl. No.:
12/022515
Inventors:
Barbra Sasu - San Bruno CA, US
Mitsuru Haniu - Thousand Oaks CA, US
Thomas Charles Boone - Newbury Park CA, US
Xiao-juan Bi - Newbury Park CA, US
Grace Ki Jeong Lee - Simi Valley CA, US
Tara Arvedson - Simi Valley CA, US
Aaron George Winters - Ventura CA, US
Keegan Cooke - Ventura CA, US
Jackie Z. Sheng - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07K 16/00
A61K 39/395
C07K 16/28
US Classification:
53038815, 4241301
Abstract:
The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.

Method For Production Of High Titer Virus And High Efficiency Retroviral Mediated Transduction Of Mammalian Cells

View page
US Patent:
20030199093, Oct 23, 2003
Filed:
Oct 1, 2002
Appl. No.:
10/260516
Inventors:
Mitchell Finer - San Carlos CA, US
Margo Roberts - Charlottesville VA, US
Thomas Dull - San Francisco CA, US
Krisztina Zsebo - Cupertino CA, US
Lu Qin - Lutherville MD, US
Deborah Farson - Oakland CA, US
Keegan Cooke - Palo Alto CA, US
International Classification:
C12N015/867
C12N007/00
C12N005/06
US Classification:
435/456000, 435/235100, 435/320100, 435/325000
Abstract:
The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.

Anti-Hepcidin Antibodies And Methods Of Use

View page
US Patent:
20110150888, Jun 23, 2011
Filed:
Apr 28, 2009
Appl. No.:
12/990137
Inventors:
Ian Foltz - Burnaby, CA
Michael Gallo - North Vancouver, CA
Keegan Cooke - Ventura CA, US
Randal R. Ketchem - Snohomish WA, US
Christopher Mehlin - Seattle WA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 39/395
C12P 21/04
C12N 5/10
C12N 15/63
C07K 16/18
C07H 21/04
A61P 29/00
A61P 7/06
A61P 35/00
A61P 9/00
US Classification:
4241391, 435 696, 435325, 4353201, 5303879, 536 2353
Abstract:
The invention relates to monoclonal antibodies that bind hepcidin and methods of making and using such antibodies. Also provided are methods of treating hepcidin-related disorders.

Il-22-Fc And Hepcidin Activity

View page
US Patent:
20130121959, May 16, 2013
Filed:
Jan 10, 2011
Appl. No.:
13/522001
Inventors:
Joseph R. Maxwell - Seattle WA, US
Jamesb B. Rottman - Sudbury MA, US
Carole L. Smith - Seattle WA, US
Keegan Cooke - Ventura CA, US
Tara Arvedson - Simi Valley CA, US
Barbara J. Sasu - Westlake Village CA, US
International Classification:
A61K 39/395
US Classification:
424 852, 5303873, 5303879
Abstract:
The invention relates to an IL-22-Fc molecule to regulate hepcidin activity/expression and/or iron export from a cell.

Method For Production Of High Titer Virus And High Efficiency Retroviral Mediated Transduction Of Mammalian Cells

View page
US Patent:
62181874, Apr 17, 2001
Filed:
Mar 11, 1999
Appl. No.:
9/266596
Inventors:
Mitchell H. Finer - San Carlos CA
Thomas J. Dull - San Francisco CA
Krisztina M. Zsebo - Woodside CA
Keegan Cooke - Palo Alto CA
Deborah A. Farson - Oakland CA
Assignee:
Cell Genesys, Inc. - Foster City CA
International Classification:
C12N 15867
C12N 1563
C12N 510
US Classification:
435457
Abstract:
The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.

Use Of Oncolytic Viruses, Alone Or In Combination With A Checkpoint Inhibitor, For The Treatment Of Cancer

View page
US Patent:
20200009204, Jan 9, 2020
Filed:
Mar 14, 2018
Appl. No.:
16/493376
Inventors:
- Thousand Oaks CA, US
Courtney BEERS - San Francisco CA, US
Keegan COOKE - Ventura CA, US
International Classification:
A61K 35/763
C07K 16/28
A61P 35/00
Abstract:
The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses, either alone or in combination with immune checkpoint inhibitors.

Substrate-Powered Energy Storage And Generation System

View page
US Patent:
20160351936, Dec 1, 2016
Filed:
Mar 16, 2016
Appl. No.:
15/072340
Inventors:
Keegan Cooke - Menlo Park CA, US
Kevin Rand - New York NY, US
International Classification:
H01M 8/16
C12N 1/20
H01M 8/04992
Abstract:
The invention is a substrate-powered energy storage and generation system employing microbial fuel cell technology utilizing electrodes located or placed within and/or on a substrate comprising soil and/or other material combined with at least one liquid in a specialized assembly to create an oxygen rich and oxygen poor environment surrounding the electrodes to create a voltage potential capable of producing sufficient current to power at least one electrical load.
Control profile
Keegan S Cooke from Ventura, CA, age ~56 Get Report